Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies

  • 📰 CNBC
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 72%

Business News News

Business Business Latest News,Business Business Headlines

Heavy debt, faltering in 2018, and cracks in the deal: Bristol-Myers Squibb's $74 billion acquisition of Celgene combines 2 troubled companies.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

That's like merging Deutsche Bank and Commerzbank. Guess 1-(-1) = 2

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bristol-Myers takes $74 bln bet against the marketThere are good reasons to buy rival oncology giant Celgene. But cost cuts don’t cover the 54 pct premium and the target’s owners get the financial benefit. Bristol is hoping for luck in the courts and multiple regulatory approvals that Celgene’s shareholders were skeptical of.
Source: Breakingviews - 🏆 470. / 51 Read more »